Table 3.
| Vaccine | Type | Schedule | Use and efficacy | Recommended populations |
|---|---|---|---|---|
| ACAM2000® (US) | Second generation Replication-competent vaccinia virus |
Single dose | Authorized for use against smallpox. Available for use against mpox by an FDA Expanded Access Investigational New Drug (EA-IND) protocol Level and duration of protective efficacy unknown. |
Mass vaccination of the general population is not recommended Primary prevention: High risk groups including men who have sex with men, people with multiple partners, healthcare providers and laboratory staff at high risk. |
| LC16m18® (Japan) | Third-generation Attenuated, minimally replication-competent vaccinia virus | Single dose | Post-exposure preventive vaccination: Close contacts of cases within four days of exposure |
|
| Imvanex® (Europe) JYNNEOS® (US) Imvamune® (Canada) |
Third-generation Replication-deficient modified vaccinia Ankara virus |
Two doses 28 days apart | Authorized for use against smallpox and mpox. Effectiveness for mpox is 36%–86% for vaccination with a single dose and 66%–89% after two doses. |
∗ACAM2000 is not recommended for people for whom replicating vaccines are contraindicated (such as pregnant women, immunocompromised people, young children) |